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Summary
Endometrial cancer (EC) is the most common type of gynecologic cancer affecting women;
however, very little research has examined relationships between psychological factors and
hypothalamic-pituitary-adrenal (HPA) axis dysregulation in this population. The current study
examined relations between depressive/anxious symptoms and salivary cortisol diurnal rhythm
and variability in women undergoing surgery for suspected endometrial cancer. Depressive and
anxious symptoms were measured prior to surgery using the Structured Interview Guide for the
Hamilton Depression Inventory (SIGH-AD). Saliva was collected four times a day for the three
days prior to surgery and then assayed by ELISA to obtain cortisol concentrations. Cortisol slopes
and intraindividual variability were then calculated across subjects. Relations between depressive/
anxious symptoms and cortisol indices were examined using multilevel modeling and linear
regression analyses. Participants were 82 women with nonmetastatic endometrial cancer. Anxious
symptoms were not associated with either cortisol slope or intraindividual variability, and
depressive symptoms were unrelated to cortisol slope. However, after controlling for presence of
poorer prognosis cancer subtypes, greater depressive symptoms (excluding symptoms possibly/
definitely due to health/treatment factors) in the week preceding surgery were significantly related
to greater cortisol intraindividual variability (β=.214; p<.05). These results suggest that depressive
symptoms prior to surgery for suspected endometrial cancer are related to greater cortisol
intraindividual variability, which is suggestive of more erratic HPA axis arousal. Future research
should examine whether mood symptoms may be associated with compromised health outcomes
via erratic HPA axis arousal in this population.
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1. Introduction
Cortisol is a glucocorticoid released by the hypothalamic-pituitary-adrenal (HPA) axis of the
central nervous system during periods of stress or challenge. This glucocorticoid is also a
potent anti-inflammatory agent with immunosuppressive properties and has also been
implicated as playing a role in tumorigenesis (Antoni et al., 2006), particularly in cancers
affecting women, who have been theorized to be differentially affected by the effects of
stress hormones (Chrousos, 2010). In vitro models of ovarian cancer suggest that cortisol
may potentiate catecholaminergic effects on tumor invasiveness (Nakane et al., 1990; Sood,
et al., 2006) and upregulate pro-angiogenic factors in the tumor microenvironment, such as
vascular endothelial growth factor (Lutgendorf, et al., 2003) and matrix metalloproteinase
expression (Lutgendorf, Lamkin, et al., 2008). In the clinical literature, breast cancer
patients with more advanced disease have greater average cortisol output compared to those
with less advanced disease (Abercrombie, et al., 2004), and flatter cortisol slope is predictive
of earlier mortality in breast cancer patients (Sephton, Sapolsky, Kraemer, & Spiegel, 2000).
In sum, research in tumor biology and clinical models suggest that greater cortisol output
and flatter cortisol rhythm (slope) may influence cancer progression in some cancers
(Antoni, et al., 2006).
Relationships between psychological factors and cortisol in female cancer populations have
also begun to emerge. For instance, breast cancer patients who suppress emotions display a
flatter cortisol rhythm (slope) (Giese-Davis, Wilhelm, et al., 2006). Behavioral stress
management techniques designed to modulate HPA-functioning in breast cancer patients
have been shown to reduce serum cortisol, and this effect may be mediated by changes in
appraisals, such as increased benefit finding and perceived ability to relax (Antoni, et al.,
2009; Phillips, et al., 2008). In response to follow-up mammography, breast cancer survivors
experience higher levels of cortisol preceding mammography and have a suppressed cortisol
response (i.e., decreasing trend of cortisol following mammography, whereas the control
group had an increased response) (Porter, et al., 2003), suggesting that breast cancer patients
may experience higher overall levels of HPA-axis output (cortisol), but experience blunted
physiological reactions to stressors (e.g., mammography). In ovarian cancer, greater cortisol
output (i.e., area under the curve) is associated with greater pro-inflammatory cytokine
(IL-6) release, and greater vegetative depressive symptoms are related to greater evening
cortisol values (Lutgendorf, Weinrib, et al., 2008). Moreover, greater functional disability,
fatigue, and vegetative depression are associated with high levels of nocturnal cortisol, as
well as less diurnal cortisol change (i.e., lower ratio of nocturnal to morning cortisol values)
in ovarian cancer (Weinrib, et al., 2010). In summary, psychological reactions to cancer may
be related to HPA-axis functioning, both in responses to cancer diagnosis and treatment and
in responses to psychological interventions.
No research to date has examined cortisol and psychological factors in endometrial cancer,
which is the most common form of gynecological malignancy and the fourth most common
cancer among women. The American Cancer Society estimates that 43,470 new cases will
be diagnosed and 7,950 women will have died from the disease in 2010. While many cases
of endometrial cancer are caught at an early stage, the 5-year survival-rate for stages III and
IV cancer are 58% and 17% respectively (American Cancer Society, 2010). In fact, while
the mortality rates of both breast cancer and ovarian cancer have decreased steadily over the
past several decades, the mortality rate of endometrial cancer has remained stable since 1991
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(American Cancer Society, 2010). These statistics highlight the fact that endometrial cancer
remains a substantial public health burden. In spite of this, there remains a paucity of
research examining relationships between psychological variables or physiological
parameters of stress, associated with receiving a diagnosis of endometrial cancer and/or
undergoing treatment for the disease. We have recently reported that a protein relevant to
carcinogenesis and psychological stress (heat shock protein 70) is related to negative mood
states in a small group of women undergoing treatment for suspected endometrial cancer
(Pereira et al., 2010); however, no published research to our knowledge has examined the
relationship between psychological factors and cortisol dysregulation in this clinical
population specifically.
Although there are a number of approaches to modeling diurnal cortisol patterns (Adam &
Kumari, 2009), there has been little consensus on the most appropriate method (Stewart &
Seeman, 2000). Many use aggregate summations of cortisol slopes across days (Kraemer et
al., 2006; Sephton et al., 2000), or characterize the total diurnal output via area under the
curve analyses (Pruessner et al., 1997). In both approaches, greater cortisol output overall
and less robust responses to endogenous cortisol production throughout the day are thought
to represent dysregulation of the HPA-axis (Keller, et al., 2006). More recently,
investigators have focused on capturing individual differences in the cortisol response
through multilevel modeling techniques (Adam & Kumari, 2009; Hruschka, Kohrt, &
Worthman, 2005), including hierarchical linear modeling (HLM) (Singer & Willet, 2003),
which allow for the estimation of individual differences. Using these methods, one may
calculate intraindividual cortisol variability or intraindividual standard deviation, a variable
that represents the amount of variability in an individual’s diurnal cortisol values when
compared to that same individual’s typical cortisol values.
Predictors of intraindividual cortisol variability (measured across days of cortisol collection
to reliably estimate erratic cortisol output) are beginning to emerge in the literature, and
include factors such as age (Tollenaar et al., 2010) and sex (Almeida, Piazza, & Stawski,
2009). Notably, relations have started to emerge between psychological factors, mood
disorders in particular, and cortisol variability. For instance, applying multilevel modeling
techniques to model intraindividual differences, greater intraindividual cortisol variability
has been shown in individuals with major depressive disorder (Peeters et al. 2004) and
remitted bipolar disorder (Havermans, Nicolson, Berkhof, & Devries, 2010) compared to
controls. Furthermore, significant associations were demonstrated between greater
depressive episode severity, more frequent depressive episode recurrence and greater
intraindividual cortisol variability (Havermans et al., 2010). Taken together, these findings
suggest that mood disturbances are associated with a more erratic pattern of cortisol
production, which may be a novel index of cortisol dysregulation.
In summary, while recent work has examined intraindividual cortisol variability in healthy
and psychiatric populations, it remains unclear how depressed mood may be associated with
this construct, as a measure of cortisol dysregulation, in cancer. Therefore, the purpose of
the present study was to examine the relationship between mood symptoms and cortisol
dysregulation in women undergoing surgery for suspected endometrial cancer. In particular,
diurnal cortisol slope and intraindividual cortisol variability were examined. Based on prior
published research, it was hypothesized that greater depressive/anxious symptoms would be
associated with a flatter cortisol slope and greater intraindividual cortisol variability.
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2. Subjects and methods
2.1. Subjects
Participants were women undergoing total abdominal hysterectomy and bilateral salpingo
oophorectomy (TAH–BSO) for suspected endometrial adenocarcinoma. Exclusion criteria
included nonfluency in English, pre-menopausal status, recurrent endometrial cancer,
neoadjuvant chemotherapy, pre-surgical radiation therapy, or primary cancer originating
from a site other than the uterine corpus. Participants were also excluded if severe
psychiatric illness was documented in the medical record.
2.2. Procedures
Recruitment for the study took place in a gynecologic oncology clinic at the University of
Florida/Shands Health Science Center between June 2004 and August of 2009. Women were
approached at their initial surgical consultation (following an abnormal endometrial biopsy)
and, if interested, completed University of Florida Institutional Review Board approved
informed consent procedures. Participants were scheduled to return to the clinic one week
later for a pre-surgical medical evaluation and were provided the following materials to
complete and return at this visit: (a) a packet of psychosocial questionnaires, and (b) a
salivary cortisol collection kit. At this pre-surgical appointment, participants returned these
materials, and study staff completed a psychosocial interview to assess depressive and
anxious symptomatology. Participants received $20 compensation for study participation.
Saliva samples were immediately transported to the laboratory for processing and storage.
Following participants’ surgeries, study staff reviewed participants’ medical charts and
abstracted history of comorbid medical conditions and tumor cellular classification, stage,
and grade data.
2.3. Assessment
2.3.1. Depression and anxiety—Depressive and anxious symptomatology during the
week prior to surgery was measured using Structured Interview Guide for the Hamilton
Anxiety and Depression scales (SIGH-AD; Williams, 1988). Doctoral students in clinical
health psychology administered the interviews. All students were trained to administer the
interview by D.P., who is also a licensed psychologist. The SIGH-AD has been used widely
in medical populations and has adequate reliability and validity in these settings (Cruess,
Antoni, Kumar, & Schneiderman, 2000). An abbreviated (24 item) version of the SIGH-AD
(15 depression items and 9 anxiety items) was used in order to reduce patient burden and to
remove items confounded with endometrial cancer symptomatology, such as genitourinary
symptoms or weight loss. Symptom severity ratings were summed to yield scores for total
depressive (possible range of 0-44) and anxious symptomatology (possible range of 0-29).
Then, depressive symptoms severity ratings judged by the interviewer as possibly or
definitely due to health/treatment factors were then subtracted from the total depressive
symptomatology score to yield a score unconfounded by health/treatment factors. This latter
score was used as a predictor in analyses.
2.3.2. Cortisol—Participants collected saliva samples at 8:00, 12:00, 17:00 and 21:00
hours for three consecutive days immediately prior to their surgery. These time points were
chosen, as they have been used in studies linking cortisol slope to clinically meaningful
outcomes, such as mortality, in cancers affecting women (Sephton et al., 2000). They were
instructed not to brush their teeth, eat or drink, and smoke for a half hour prior to collecting
saliva samples. Participants were asked to record the exact time of collection, in an effort to
verify their adherence with instructions. Participants were asked to refrigerate the saliva
samples until they were able to bring them to their pre-operative study visit, and they were
provided with a small, insulated cooler to transport the samples back to the research team.
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Once received by study personnel, saliva samples were frozen at −80 degrees Celsius until
they were shipped to Salimetrics Inc. (State College, PA) for assaying. Samples were
assayed for salivary cortisol in duplicate using a highly sensitive enzyme immunoassay
(Salimetrics, State College, PA). The test used 25 μl of saliva per determination, has a lower
limit of sensitivity of 0.003 μg/dl, standard curve range from 0.012 μg/dL to 3.0 μg/dL, an
average intra-assay coefficient of variation of 3.5% and an average inter-assay coefficient of
variation of 5.1%. Method accuracy determined by spike and recovery averaged 100% and
linearity determined by serial dilution averaged 91.7%.
2.3.3. Control variables—Demographic variables (age, race/ethnicity, yearly income and
education level) and relevant behavioral factors (tobacco, alcohol and other drug use) were
collected via self-report measures and face-to-face interviews. Health factors possibly
associated with cortisol were also obtained from medical chart review, including tumor
stage/grade (Abercrombie et al., 2004) and a sum of the number of medications being taken
that may affect HPA-axis functioning (Progesterone, NE-dopamine reuptake inhibitors, anti-
hypertensives, adrenocortical steroids). Medical comorbidity was calculated using the
Charlson Comorbidity index. This index tallies all pre-existing medical conditions (e.g.,
congestive heart failure, diabetes) and creates a sum score for each individual (Charlson,
Pompei, Ales, & MacKenzie, 1987). In addition, adenocarcinoma subtype (Type I versus
Type II) was covaried. Type I adenocarcinoma includes endometrioid adenocarcinoma, the
most common subtype. Type I adenocarcinoma is considered to be a “low grade” variant
carrying a favorable prognosis. Type II adenocarcinomas include uterine papillary serous
and clear cell adenocarcinomas, both of which are considered aggressive “high grade”
variants with poorer prognoses. To control for the potential relationship between tumor
burden and cortisol rhythms (Abercrombie et al., 2004), a dichotomous variable was created:
participants with preinvasive endometrial disease (complex hyperplasia with atypia) and
Type I adenocarcinoma were coded as “0,” while those with Type II adenocarcinomas (clear
cell, mucinous, or uterine papillary serous) were coded as “1.”
2.4. Statistical analyses
2.4.1. Data preparation—Descriptive statistics were examined for each variable of
interest. Normal probability histograms were examined for all cortisol outcome variables. If
deemed non-normal, outliers (values greater than 3 standard deviations from the mean) were
removed and, if necessary, an appropriate statistical transformation was applied to ensure
adequate characteristics of normality. All analyses were conducted with SPSS Version 17.0
(Chicago, IL).
2.4.2 Modeling and predicting diurnal cortisol slope—Multilevel modeling (MLM)
was applied to examine potential relationships between psychological variables of interest
and cortisol. MLM has been increasingly used to model the diurnal time trends observed in
cortisol (Adam & Gunnar, 2001; Almeida et al., 2009; Hruschka et al., 2005). Following
Singer and Willett (2003), only the k-2 polynomial trends are identified; therefore, we tested
linear and quadratic time trends. The quadratic time trend was included in the final model
after removing the collinear effects of the linear time trend. To make estimates of cortisol
more interpretable, saliva collection times were rescaled to have the starting value equal
zero while keeping the original scale between points of time to preserve the original distance
between points of collection. In addition, given that participants recorded the actual time at
which saliva was collected, the average sample time at which each of the four cortisol
measurements were taken (over the three days) was used as the time-of-day predictor. Data
were represented by three levels of data collection: time of cortisol collection within day of
collection (Level 1), day of collection (Level 2) and between-persons differences (Level 3).
Analyses revealed that the Level 2 “Day” effect was not significant and contributed to
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model convergence problems; it was therefore eliminated from all analyses that followed.
The final analyses included two levels of analysis: time within day and between-person
differences in cortisol. To examine between-person predictors of interest, two separate
models were run: one including SIGH-AD Depression as a continuous predictor and one
including SIGH-AD Anxiety as a continuous predictor. These were entered as Level 2
predictors to explain individual differences in initial value of cortisol (SIGH-AD Depression
and Anxiety main effects as two separate models) and cortisol slope (SIGH-AD
Depression*time interaction and SIGH-AD Anxiety*time interaction as two separate
models). Both depression and anxiety scores from the SIGH-AD were centered to ensure
that parameter estimates were more interpretable (Blackwell, de Leon, & Miller, 2006). The
following control variables were examined and included in the analyses if they significantly
predicted the cortisol time trend or if they significantly improved the model fit based on
comparing −2 log likelihood ratios in maximum likelihood estimation: sum of the number of
relevant medications prescribed and used (listed above), current smoking status (recoded as
a dichotomous variable; 0=current non-smoker, 1=current smoker), cancer stage, tumor
grade, Type I vs. Type II subtypes, and Charlson Comorbidity score.
2.4.3. Modeling and predicting intraindividual cortisol variability—MLM was
also used to examine intraindividual variability in cortisol output. In order to examine
variability in the context of data with significant time trends, the data were first “detrended,”
in order to eliminate the time trend as a potential confound (Hultsch & MacDonald, 2004).
To this end, MLM was applied to accurately model the anticipated diurnal time trend of
cortisol of cortisol production throughout the day, and the residuals of each individual’s
regression were saved. This approach is similar to what has been called “beep-level
variance” (Peeters, Nicolson, & Berkhof, 2004) cortisol pulsatility (Young, Abelson, &
Lightman, 2004) and approximate entropy in cortisol production (Posener, et al., 2004),
which refer to what level individuals vary from their typical cortisol output, after controlling
for the anticipated diurnal time trend.. In the present study, the standard deviation of each
individual’s residual was then saved as a separate variable, creating a variable of cortisol
intraindividual variability (Stuart, Macdonald, Hultsch & Bunce, 2006). Bivariate Pearson
correlation analyses were conducted to examine the relationship between cortisol variability
and the psychological variables of interest (depression/anxiety). Any significant
psychological variable-cortisol variability correlations were then explored further using
hierarchical regression analyses (ordinary least squares) while controlling for variables




One hundred thirty-four women were enrolled into the study. Three of these participants
were excluded for having adenomyosis (a benign endometrial condition) and/or complex
hyperplasia without atypia (a hyperplastic condition with very little likelihood of
progressing to invasive cancer) following surgery. Of the remaining 131 participants, 26
were excluded, as they did not contribute any psychosocial or cortisol data due to systematic
data collection problems (e.g., participant was discharged from clinic without the knowledge
of the study researchers and before any data could be collected). Of the 105 remaining
participants, 82 contributed complete psychosocial data and more than 1 saliva sample.
Analyses were conducted on these 82 participants. Comparison of these 82 participants to
the 23 who provided only partial psychosocial and/or cortisol data revealed that there were
no statistically significant differences on major demographic, psychosocial, or cancer-related
variables between the final sample of 82 and the 23 providing only partial data (see Table 1).
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Participants’ raw cortisol values were examined for normality, and two cortisol values were
determined to be 3 standard deviations from the mean and were eliminated from further data
analyses. After the removal of these outliers, cortisol data displayed adequate characteristics
of normality. Mean raw cortisol values for each time of collection are presented in Figure 1.
3.3. Depressive/anxious symptomatology and diurnal cortisol slope
Depressive symptomatology scores ranged from 0 to 30 (M=6.66; SD=5.66), while anxious
symptomatology scores ranged from 0 to 21 (M=5.17; SD=4.01). Depressive
symptomatology scores were non-normally distributed, and therefore a square root
transformation was applied to ensure adequate characteristics of normality. As previously
stated, multilevel modeling was applied to model the cortisol data and account for the
diurnal time trend typically observed in cortisol rhythms. As expected, a significant negative
linear time trend was observed in cortisol (β = −0.015, SE = .0012, p<.001) as well as a
significant positive quadratic trend at the end of the day (β = .0016, SE = .0003, p<.001).
There was not a significant trend of cortisol across days (β = .0015, SE = .0065, p=.82).
Also as expected, there was significant variance, or significant random effects, in both the
first measurement of cortisol at 8AM (p<.001), linear time trend within the day (p<.001).
Out of the possible control variables investigated (current smoking status, cancer stage,
tumor grade, adenocarcinoma subtype, medication use1), only the Charlson comorbidity
score was significantly related (p<.05) to cortisol slope in the multilevel model; therefore,
only comorbidity score was retained as a control variable in the depression and anxiety
conditional growth model2.
After controlling for comorbidity, neither depressive nor anxious symptoms predicted the
initial value of cortisol (β = 0.015, SE = 0.014, p=.29; and β = 0.0014, SE = 0.0038, p=.72;
respectively). Similarly and contrary to hypotheses, neither depressive nor anxious
symptoms predicted linear cortisol slope across the three days preceding surgery (β =
−0.00044, SE = 0.00033, p = .19; and β = −0.00025, SE = 0.00029, p = .41; respectively).
Furthermore, neither depressive nor anxious symptoms were related to the positive quadratic
trend observed in the cortisol rhythm within day (data not shown).
3.4. Depressive/anxious symptomatology and intraindividual cortisol variability
Intraindividual cortisol variability data were examined for normality. Cortisol variability
data was non-normal and therefore a square root transformation was applied. After applying
this transformation, the data displayed adequate characteristics of normality. Of the control
variables examined, only adenocarcinoma subtype was associated with intraindividual
cortisol variability; specifically, participants with Type II adenocarcinomas had significantly
lower cortisol variability than those with Type I adenocarcinomas, t(81)=2.33, p=.023.
Using Pearson correlations, intraindividual cortisol variability was not related to anxiety
symptoms, r (82) = .110; p=ns. However, intraindividual cortisol variability was marginally
significantly associated with depressive symptomatology, r(82) = .197; p=.07. Given the
significant group difference in intraindividual cortisol variability between Type I and Type
II adenocarcinomas, a hierarchical regression (ordinary least squares regression in which
predictors are entered in theoretically ordered blocks) was conducted controlling for
1Only 8 patients were taking corticosteroids (primarily inhalers) at the time of data collection. The models presented were re-run
excluding these participants and the results were not affected (data not shown).
2Both MLM models with comorbidity index as a control and without controls were estimated. The inclusion of Charlson comorbidity
index scores did not significantly improve model fit (-2 log likelihood chi square comparison); however, it was retained as a control
variable given that comorbidity significantly predicted cortisol slope.
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presence of Type II adenocarcinomas. After controlling for the presence of aggressive, high-
grade adenocarcinoma variants, greater depressive symptomatology was significantly
associated with greater intraindividual cortisol variability (β=.214; p<.05) (Figure 2).
To further illustrate the relationship between depressive symptomatology and intraindividual
cortisol variability, raw cortisol values were plotted for the five participants reporting the
lowest depressive symptoms (i.e., no depressive symptoms) prior to surgery (Figure 3a) and
the five participants with the greatest depressive symptoms prior to surgery (Figure 3b). As
suggested by these Figures, compared to participants with no depressive symptoms,
participants reporting the greatest depressive symptoms demonstrated greater dispersion of
raw cortisol values from their individual regression slopes.
4. Discussion
Recently, Garssen, Boomsma, and Beelen (2010) identified research examining relations
between psychological factors and biological stress systems during the perioperative period
in cancer as a high priority area (Garssen, Boomsma, & Beelen, 2010). In spite of the fact
that (a) endometrial cancer is one of the most common cancers among women and (b) major
abdominal surgery is the primary treatment for most early stage, endometrioid
adenocarcinomas, very few published studies have examined psychosocial – biological
stress system relationships in endometrial cancer. As such, the purpose of the present study
was to examine the relationship between depressive/anxious symptomatology and
intraindividual cortisol variability and cortisol slope in women proceeding to TAH-BSO for
suspected endometrial cancer.
Results revealed that, in contrast to hypotheses and related prior research (Bhattacharyya,
Molloy, & Steptoe, 2008), depressive symptomatology was not related to cortisol slope.
There are several possible explanations for this result. First, the SIGH-AD queried only
about the incidence and severity of mood symptoms in the week prior to participants’
scheduled surgeries, and as such, it did not allow for a diagnosis of depression or an
assessment of the chronicity of mood symptoms. It is possible that the physiological
resistance to glucorticoid secretion that would yield a flattened cortisol slope may only be
observed among those with major depressive disorder or prolonged, moderate to severe
depressive symptomatology (Miller, Cohen, & Ritchey, 2002). As such, the nonsignificant
results of the present study may not be comparable to those obtained among patients with
severe or long-standing mood symptoms. Second, participants in the present sample reported
relatively low levels of depressive symptomatology, and the nonsignificant relationship
between depression and cortisol slope may be due to the low amount of variance in
depressive symptomatology. Third, our study may have been underpowered to detect an
effect in the multilevel model tested in our study.
However, consistent with hypotheses, greater depressive symptomatology in the week prior
to surgery was significantly associated with greater intraindividual cortisol variability. These
findings are in accord with prior work demonstrating higher cortisol variability in major
depressive disorder (Peeters, et al., 2004) and episode severity in remitted bipolar disorder
(Havermans, et al., 2010). However, the clinical implications of these results are unclear at
the present time, partly because no published research has examined the relationship
between intraindividual cortisol variability and clinical outcomes in cancer. It is possible
that greater intraindividual cortisol variability may be indicative of greater circadian rhythm
disruption. For instance, it is well established that individuals with chronic and severe
disruptions in the sleep-wake cycle (i.e., a circadian rhythm) demonstrate greater variability
in subjective and objectives measures of sleep efficiency than nonimpaired controls (Buysse,
et al., 2010). Extrapolating from this research, it is possible that high levels of
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intraindividual cortisol variability are indicative of HPA axis functioning that is erratic,
unpredictable, and inappropriately under- and over-responsive to the actual demands of the
host and his/her environment. While it is presently unknown whether high intraindividual
cortisol variability has negative long-term health implications in cancer, it is noteworthy that
there is some research suggesting that circadian rhythm disruption may be associated with
carcinogenesis (Sephton & Spiegel, 2003; Touitou, Bogdan, Levi, Benavides, & Auzeby,
1996). Future research should examine intraindividual cortisol variability, as well as other
indicators of circadian disruption such as sleep disturbances, longitudinally to establish
whether they are associated with cancer outcomes, such as disease free survival.
Contrary to hypotheses, anxiety was not significantly associated with cortisol slope or
intraindividual cortisol variability in the present study. Prior published research has
suggested a relationship between anxiety and cortisol (AUC) in breast cancer patients
(Giese-Davis, DiMiceli, Sephton, & Spiegel, 2006; Vedhara, et al., 2003). However,
substantial methodological differences exist between these studies and the present study. For
example, Giese-Davis and colleagues (2004) found that those who repressed emotions and
high-anxious groups had significantly flatter diurnal slopes when compared to cortisol
profiles of those classified as self-assured in this sample. This finding suggests that there
may be important moderators of the relationship between anxiety and cortisol slope in
women with cancer, a hypothesis that warrants future examination. Antoni and colleagues
(2009) recently found that Cognitive Behavioral Stress Management (CBSM) improved
mood symptoms, lowered cortisol levels, and promoted adaptive cytokine regulation in
women with breast cancer. However, this investigation did not uncover a significant
mediating effect of anxiety on the relationship between reductions in cortisol and
participating in CBSM, suggesting that reductions in cortisol may not always be driven by
reductions in anxiety. Future investigations should remain mindful to include potential
mediators/moderators of anxiety-cortisol relationships.
The findings of the present study should be interpreted in light of several limitations. First,
the study design was nonexperimental, and as such, causal interpretations cannot be made.
Future research should employ experimental designs to assess causality. Second, although
the study design captures three days worth of data, only limited cortisol variance or
fluctuation is captured across the 12 time points. A larger sample with more cortisol
measurements may yield more robust findings, or possibly, different results. Third, the
mixed model analysis was only able to accurately model a portion of the cortisol trend.
Therefore, the residuals used to calculate the intraindividual cortisol variability may not
accurately control for the entire time trend seen in the diurnal cortisol variation within the
day. Applying the residuals to additional mixed model approaches may be warranted, as
others have suggested (Almeida, Piazza, & Stawski, 2009). In future investigations,
including different error structures and autocorrelations between timepoints of cortisol
collection in calculating cortisol variability may also be informative (Peeters et al., 2004).
Fourth, the study design lacked a benign-disease only comparison group. Inclusion of a
comparison group would allow for the examination of differences in mood/cortisol
relationships between women with surgically-staged gynecologic cancer and those with
surgically-confirmed benign disease in addition to being able to tease out the contribution of
cancer-related biological factors to psychological factors-cortisol relationships. Finally, the
study sample had a low percentage of racial and ethnic minority women. Given that African-
American women with endometrial cancer have poorer survival rates than Caucasian women
(Yap & Matthews, 2006), the present sample’s lack of racial/ethnic diversity may limit the
ability to generalize the study’s findings to women who carry the highest disease burden.
Future research should oversample racial/ethnic minority women affected by gynecologic
cancers in order to maximize generalizability.
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In summary, this study found that greater depressive symptoms were significantly related to
greater intraindividual cortisol variability but unrelated to linear cortisol slope in a group of
women undergoing surgery for suspected endometrial cancer. Anxious symptoms were not
significantly related to either outcome variable of HPA-axis dysregulation. Future research
should examine whether depressive symptoms may be associated with meaningful negative
clinical outcomes in women undergoing surgery for suspected endometrial cancer through
its effects on intraindividual cortisol variability, which may represent a novel index of HPA
axis-dysregulation.
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Average cortisol values for the four time points of saliva collection.
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Regression of depressive symptoms predicting cortisol variability. The x and y axes
represent z-scores, demonstrating a positive relationship between depressive symptoms and
cortisol variability, after controlling for adenocarcinoma subtype.
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Cortisol variability: participants with the lowest depressive (LD) symptom scores. Cortisol
values and corresponding regression lines are displayed. These 5 participants reported no
depressive symptoms prior to surgery. Each line represent the individual’s cortisol slope,
with characters representing actual cortisol values. These select participants demonstrate low
cortisol variability, as their actual cortisol values are in close proximity to their average
pattern of cortisol output.
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Cortisol variability: participants with the highest depressive (HD) symptom scores. These 5
participants reported the highest depressive (HD) symptom scores of the study sample. High
cortisol variability is represented by the plotted cortisol values (represented here by the
individual’s average patterr of cortisol output).
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